Regocent (Tablet 40 mg)

Colorectal Cancer: Regocent is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine, oxaliplatin-and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. Gastrointestinal Stromal Tumors: Regocent is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with Imatinib Mesylate and Sunitinib Malate. Hepatocellular Carcinoma: Regocent is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Sorafenib. * রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'

Add to cart